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Colorectal cancer (CRC) is a major cause of cancer mortality. 
Whereas some patients respond well to therapy, others do not, 
and thus more precise, individualized treatment strategies 
are needed. To that end, we analyzed gene expression profiles 
from 1,290 CRC tumors using consensus-based unsupervised 
clustering. The resultant clusters were then associated with 
therapeutic response data to the epidermal growth factor 
receptor–targeted drug cetuximab in 80 patients. The results of 
these studies define six clinically relevant CRC subtypes.  
Each subtype shares similarities to distinct cell types 
within the normal colon crypt and shows differing degrees 
of ‘stemness’ and Wnt signaling. Subtype-specific gene 
signatures are proposed to identify these subtypes. Three 
subtypes have markedly better disease-free survival (DFS) 
after surgical resection, suggesting these patients might be 
spared from the adverse effects of chemotherapy when they 
have localized disease. One of these three subtypes, identified 
by filamin A expression, does not respond to cetuximab but 
may respond to cMET receptor tyrosine kinase inhibitors in 
the metastatic setting. Two other subtypes, with poor and 
intermediate DFS, associate with improved response to the 
chemotherapy regimen FOLFIRI1 in adjuvant or metastatic 
settings. Development of clinically deployable assays for these 
subtypes and of subtype-specific therapies may contribute  
to more effective management of this challenging disease.
Previous studies have identified molecular subtypes of various human 
cancers by gene expression profiling2–8, including CRC subtypes9,10. 
However, these subtypes have not been associated with outcomes in 
patients treated with specific therapeutic interventions. Therefore, 
we sought to refine the approach of molecular classification of 
CRC by associating gene expression profiles of CRC tumors with 
corresponding clinical response to cetuximab. We first used consensus- 
based non-negative matrix factorization (NMF)11 to cluster two pub-
lished gene expression data sets (GSE13294 (ref. 12) and GSE14333 
(ref. 13)) derived from resected primary CRCs (core data sets, 
n = 445). These data were corrected for batch effects and merged using 
the distance-weighted discrimination method5,14 before clustering. 
This analysis defined five distinct high-consensus molecular subtypes 
of CRC (Supplementary Fig. 1a–e and Supplementary Results and 
Discussion). We used silhouette width2,15 to identify samples that 
most closely represent one of these five molecular subtypes, and 
this analysis yielded a ‘core’ set of 387 CRC tumors (Supplementary 
Results and Discussion and Supplementary Fig. 1f). We identified 
markers associated with the five subtypes using significance analysis 
of microarrays (SAM16, false discovery rate (FDR) = 0), followed 
by prediction analysis for microarrays (PAM17, nearest shrunken 
centroids–based method) to identify 786 subtype-specific signature 
genes (a collection dubbed CRCassigner-786; Fig. 1a, Supplementary 
Results and Discussion, Supplementary Data and Supplementary 
Table 1b) with the lowest prediction error.
We named the five subtypes by the genes preferentially expressed 
in each (Fig. 1a,b and Supplementary Fig. 2): (i) goblet-like, defined 
by high mRNA expression of goblet-specific MUC2 and TFF3 
(ref. 18); (ii) enterocyte, defined by high expression of enterocyte-
specific genes18; (iii) stem-like, with high expression of Wnt signaling 
targets plus stem cell, myoepithelial and mesenchymal genes and low 
expression of differentiation markers; (iv) inflammatory, marked by 
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comparatively high expression of chemokines and interferon-related 
genes; and (v) transit-amplifying, a heterogeneous collection of 
samples with variable expression of stem cell and Wnt-target genes. 
We then condensed the 786-gene signature into two smaller sub-
signatures. One, dubbed as CRCassigner-30, has 30 genes with high 
PAM scores and characteristics of specific subtypes that might be 
used clinically for robust definition of these subtypes (Fig. 1b and 
Supplementary Table 1b). The second comprises a reduced feature set 
of seven genes (CRCassigner-7) that we explored for possible develop-
ment as a classification assay using either quantitative RT-PCR (qRT-
PCR) or immunohistochemistry. Six of these seven markers could 
be used to classify 50% of 72 patient-derived tumors (10 out of 19 
samples using qRT-PCR and 26 out of 53 samples using immunohisto-
chemistry) into one of the five CRC subtypes (Fig. 1c, Supplementary 
Fig. 2g, Supplementary Table 1c,d and Supplementary Methods). 
The use of the seventh CRCassigner-7 gene is discussed below and 
in the Supplementary Results and Discussion. The inflammatory 
subtype currently cannot be defined using an immunohistochemistry 
assay owing to the lack of antibodies that identify the markers for 
this subtype. Development of a clinically deployable qRT-PCR assay 
will require identification of reference genes and precisely defined 
decision thresholds.
We further validated the colon cancer subtypes in seven inde-
pendent patient gene expression profile data sets (n = 744), includ-
ing a recent The Cancer Genome Atlas study9, by projecting the 
CRCassigner-786 genes onto the data sets and then performing 
NMF consensus clustering (Supplementary Fig. 3, Supplementary 
Table 2 and Supplementary Results and Discussion). Four of our 
five subtypes were also represented in a panel of human CRC cell 
lines19,20 (n = 51; see Supplementary Results and Discussion for 
identification of subtypes in cell lines, Fig. 1d, Supplementary 
Fig. 4a–c and Supplementary Table 2c). In three cases, we showed 
that the subtype signature was stably maintained when subtyped CRC 
lines were grown as xenograft tumors in mice and analyzed for marker 
expression by qRT-PCR (Supplementary Fig. 4d,e).
We next examined the association of CRC subtypes with DFS 
after surgery for 197 patients in one of the core CRC data sets, 
GSE14333 (ref. 13), for which reported follow-up data were avail-
able. We first evaluated DFS for all the samples irrespective of stage 
or treatment (adjuvant chemotherapy or chemoradiotherapy21). This 
did not reveal a significant association between subtype and DFS 
(P = 0.12; log-rank test; Supplementary Results and Discussion, 
Supplementary Fig. 5b and Supplementary Table 3). We did, how-
ever, detect significant associations of subtypes with DFS within 
treatment subgroups. In untreated patients, stem-like–subtype 
tumors had the shortest DFS, inflammatory and enterocyte subtypes 
had intermediate DFS, and transit-amplifying and goblet-like sub-
types showed a good prognosis (P = 0.0003; n = 120; log-rank test, 
Fig. 1e). However, there was no significant association between sub-
type and DFS in the treated patients (n = 77, Supplementary Fig. 5c). 
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Figure 1 Classification of colorectal tumors and cell lines into subtypes. (a,b) Heatmaps showing CRC subtypes in tumors (from two merged  
core data sets: GSE13294 and GSE14333) defined by CRCassigner-786 (a) and CRCassigner-30 gene signatures (b). (c) Immunohistochemistry assays 
of patient CRC samples using candidate CRC subtype-specific markers (four from the CRCassigner-7) to assign subtypes. For immunohistochemistry, 
each subtype-specific marker was scored +, ++ or +++ for weak, moderate or strong intensity of staining, respectively; see Supplementary Methods 
and Supplementary Table 1d for more information. Scale bar represents 100 µm. (d) Heatmap showing CRC tumor subtypes from the core tumor data 
sets described in a and b merged with cancer cell line data19,20. (e) Differential DFS amongst the CRC subtypes from untreated patients from the 
GSE14333 data set plotted as Kaplan-Meier survival curves. (f) Heatmap depicting known MSI or MSS status for each of the colorectal tumor  
subtype samples from the data set GSE13294. CFTR, cystic fibrosis transmembrane conductance regulator; MUC2, mucin 2; TA, transit amplifying; 
TFF3, trefoil factor 3; ZEB1, zing finger E-box–binding homeobox-1. 
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There was a trend suggesting that adjuvant chemotherapy or chemo-
radiotherapy preferentially improved DFS in patients with stem-
like–subtype tumors, whereas both treatments were associated 
with a detrimental effect in the transit-amplifying and goblet-like 
subtypes (Supplementary Fig. 5a–h). These results suggest that 
stem-like tumors might be preferentially responsive to adjuvant 
chemotherapy or chemoradiotherapy, whereas transit-amplifying–  
and goblet-like–subtype tumors might not benefit from these treat-
ments. As there were only 43 events of tumor recurrence among the 
treated and untreated samples, additional studies involving larger 
patient data sets will be needed to test the validity of the suggested 
relationships between subtype, treatment and DFS.
We next compared our subtypes with the well-established micro-
satellite stability (MSS) or instability (MSI) phenotypes using 
GSE13294 (n = 155)12. We observed that 94% (n = 36) of the 
inflammatory-subtype samples showed MSI, whereas 86% (n = 42) 
of the transit-amplifying and 67% (n = 21) of the stem-like subtypes 
were MSS (Fig. 1f). We obtained consistent results by associating MSI 
status for tumors previously classified with our subtype signature and 
querying their core data sets for MSI status using a published MSI gene 
signature22 and the nearest template prediction (NTP) algorithm23 
(Supplementary Fig. 5i–k). Although there are clear associations 
between MSI or MSS status and specific subtypes, the transcriptional 
signatures and subtype definitions allow refinement beyond what can 
be achieved by annotating microsatellite stability status.
The normal colon is composed of cell types with varying degrees 
of differentiation potential and specialized functions24. Although 
colonic stem cells are thought to be the cell of origin for CRC, more 
differentiated cells may also be susceptible to transformation18,25,26. 
We assigned cell of origin or phenotypes to the transcriptional CRC 
subtypes defined here using a published gene signature that discrimi-
nates between the normal colon crypt top (where terminally differen-
tiated cells are transiently located) and the normal crypt base (where 
stem cells and their partially differentiated derivatives reside)27. 
We used the NTP algorithm23 (Supplementary Results and 
Discussion and Fig. 2a) to show that 98% (n = 44) of the stem-like 
subtype tumors were significantly (FDR < 0.2) associated with the 
crypt base signature. In addition, we found that several published stem 
cell–specific gene and pathway signatures were significantly associated 
with the stem-like subtype (Supplementary Fig. 6a,b). In contrast, 
92% (n = 52) and 82% (n = 33) of samples from the enterocyte and 
goblet-like subtype tumors, respectively, were associated with crypt 
top by their concordant gene signatures. The inflammatory subtype 
was not associated with either the crypt base or top (about 75% of the 
samples were undetermined with FDR > 0.2). Notably, 59% (n = 59) 
of the transit-amplifying–subtype tumor samples had a crypt-top 
signature with low expression of the Wnt signaling targets LGR5 and 
ASCL2 (ref. 18). In contrast, the remaining transit-amplifying–subtype 
tumors were significantly associated with the crypt base (Fig. 2a) and 
showed high mRNA expression of the stem and progenitor markers 
LGR5 and ASCL2 (Supplementary Fig. 6c). This observation suggests 
that the transit-amplifying subtype can be further subdivided.
The colon-crypt base is composed predominantly of stem and 
progenitor cells that are known to have high Wnt activity28, and 
we identified several canonical Wnt gene targets as components of 
our stem-like–subtype signature (Supplementary Table 1b). The 
majority of the stem-like–subtype tumors from the core CRC data 
set were associated with high Wnt activity signature28, as observed 
in the colon crypt top or base gene signature comparison, whereas 
the enterocyte and goblet-like subtypes were not (Fig. 2a). We tested 
this association by performing an in vitro Wnt activity assay (TOP-
flash) on subtype-specific CRC cell lines. We observed that 57%  
(n = 7) of stem-like–subtype cell lines showed high Wnt activity (above 
the median TOP-flash signal), as compared to 17% (n = 6) among 
cell lines from the other subtypes (Fig. 2b). We further tested this 
observation by performing qRT-PCR and immunofluorescence assays 
on a panel of CRC cell lines using known CRC markers of differentia-
tion, Wnt signaling or stemness28. This analysis confirmed that the 
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Figure 2 Cellular phenotype and Wnt signaling 
in the CRC subtypes. (a) Heatmap showing 
association of colon-crypt location (top or base) 
and Wnt activity in the patient colorectal tumors 
from the core data sets revealed by applying 
specific signatures27,28 using the NTP algorithm. 
In these analyses, statistics include only those 
samples that were predicted with FDR < 0.2 
(see Supplementary Results and Discussion for 
statistics from all samples including those with 
FDR > 0.2). (b) TOP-flash assay depicting Wnt 
activity in CRC cell lines. (c–e) qRT-PCR analysis 
depicting the average expression of Wnt signaling 
pathway (c), stem cell (d) and differentiation-
specific (e) markers in a set of CRC subtype-
representative cancer cell lines (HT29 and LS174T 
for goblet-like; LS1034, NCI-H508 and SW948  
for transit-amplifying; and SW48, HCT8 and 
SW620 for the stem-like subtype). The qRT-PCR 
data is plotted relative to the housekeeping gene 
RPL13A. Error bars represent the s.d. of technical 
replicates from a representative experiment.  
(f) Immunostaining analyses for the differentiation 
markers KRT20 are presented in red, and nuclei 
are counterstained with DAPI (blue). HCT116 and 
COLO320 belong to the stem-like, SW1417 and 
SW948 belong to transit-amplifying, and HT29 
and LS174T belong to the goblet-like subtypes. 
Scale bar represents 15 µm.
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stem-like subtype was the least differentiated and had the highest 
expression of Wnt signaling and stem cell markers. The goblet-like 
subtype, in contrast, had a well-differentiated gene expression pattern 
with comparatively low expression of the stem cell and Wnt markers 
(Fig. 2c–f and Supplementary Fig. 2). These results provided further 
evidence that the stem-like subtype indeed has a stem or progenitor 
cell phenotype, whereas the goblet-like and enterocyte subtypes have 
a more differentiated phenotype.
The epidermal growth factor receptor (EGFR)-specific mono-
clonal antibody cetuximab, which is a mainstay of treatment for 
metastatic CRC with wild-type KRAS29,30, has failed to show signifi-
cant benefit in the adjuvant setting, irrespective of KRAS genotype31. 
We correlated subtypes with cetuximab response using a CRC liver 
metastases microarray (Khambata-Ford) data set32 annotated with 
therapeutic responses to cetuximab in 80 patients. NMF consensus 
clustering with the CRCassigner-786 genes showed that three of 
our five subtypes were present in this collection of 80 CRC samples 
(Fig. 3a and Supplementary Fig. 7a). We identified a subgroup 
of samples (n = 26) (termed ‘unknown’) with a gene expression 
profile that was highly similar to that of normal liver (Fig. 3a and 
Supplementary Table 4a). These samples were not analyzed further. 
Within the remaining metastatic CRCs, only 23% (out of 22 samples 
with known cetuximab response) from the goblet-like and stem-
like subtypes responded to cetuximab. However, 54% (n = 26) of 
patients with transit-amplifying–subtype cancer benefitted from 
cetuximab, whereas the other 46% of patients had progressive disease. 
In this case, complete response, partial response and stable disease 
were considered as beneficial. These data suggest that the transit- 
amplifying subtype designation includes two populations that differ 
in cetuximab sensitivity (Fig. 3a).
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Figure 3 Differential sensitivity among CRC subtypes to cetuximab. (a) Heatmap showing individual responses of patients with metastatic CRC  
(Khambata-Ford data set32) to cetuximab treatment and their association with subtypes. (b) Cetuximab response in CRC subtype–specific cell lines is 
plotted as percentage of proliferation of treated cells (cetuximab, 62.5 µg ml−1) normalized to vehicle-treated control. (c) Cetuximab response in transit-
amplifying sub-subtype specific cell lines are plotted as percentage colony formation of treated cells (cetuximab, 15.6 µg ml−1) normalized to vehicle-
treated cells. (d–g) Cetuximab response in transit-amplifying sub-subtype–specific xenograft tumors using the CS-TA cell lines NCI-H508 (d) and SW1116 
(e) and the CR-TA cell lines LS1034 (f) and SW948 (g). (h) Heatmap depicting differential gene expression patterns and the KRAS mutation status 
between CR-TA and CS-TA subtypes (Khambata-Ford data set). (i) Kaplan-Meier curve of differential DFS based on FLNA expression in transit-amplifying 
subtype samples (Khambata-Ford data set). The expression of FLNA was median-centered across all the 80 samples that belong to different subtypes; 
those above median were considered as ‘FLNA high’, and those below the median were considered as ‘FLNA low’. (j) Differential response to the cMET 
inhibitor PHA-665752 (625 nM) in CR-TA and CS-TA subtype-specific cell lines, plotted relative to vehicle-treated cells. Error bars represent the s.d. of 
technical replicates (triplicates in b,c and j, where as the sample sizes are indicated for d–g in the figure) from a representative experiment. *P < 0.05. 
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We explored this segregation in responsiveness by assessing cell pro-
liferation and colony-forming potential in cultured CRC cell lines repre-
senting different subtypes and then analyzing their growth as xenograft 
tumors, with and without cetuximab treatment. We found that a sub-
set of transit-amplifying–subtype cell lines was selectively sensitive to 
treatment (Fig. 3b–g and Supplementary Fig. 7b,c). Specifically, the 
proliferation of two transit-amplifying–subtype cell lines (NCI-H508 
and SW1116) was significantly impaired by cetuximab both in vitro 
and in xenograft tumors, compared to vehicle controls (Fig. 3b–g 
and Supplementary Fig. 7b,c). Notably, tumors from the NCI-H508 
cell line had not recurred 45 d after the conclusion of treatment. In 
contrast, two other transit-amplifying cell lines showed resistance to 
cetuximab in vitro (LS1034 and SW948), and both showed progres-
sive growth as xenograft tumors during treatment with cetuximab 
(Fig. 3b–g). The clinical and experimental data collectively sup-
port the division of the transit-amplifying–subtype tumors and cell 
lines into two sub-subtypes: cetuximab-sensitive transit-amplifying 
(CS-TA) and cetuximab-resistant transit-amplifying (CR-TA). This 
delineation increases the number of CRC subtypes to six.
We next performed SAM-based differential gene expression analy-
sis on the transit-amplifying subtype tumors from the Khambata-Ford 
data set32 (transit-amplifying signature; FDR = 0.1). This revealed 
that CS-TA tumors expressed significantly higher levels of the EGFR 
ligands epiregulin (EREG) and amphiregulin (AREG), which are 
known to be positive predictors of cetuximab response32, as compared 
to CR-TA tumors (Fig. 3h and Supplementary Fig. 7d). In contrast, 
filamin A (FLNA), which regulates the expression and signaling of the 
cMET receptor33, was overexpressed in CR-TA compared to CS-TA 
(Fig. 3h and Supplementary Fig. 7e). This correlation was further 
confirmed using receiver operating curve analysis (Supplementary 
Fig. 7f,g). High FLNA expression was significantly (P = 0.001; 
log-rank test; n = 26, Fig. 3i) associated with shorter progression-free 
survival only within the transit-amplifying–subtype tumors. However, 
FLNA expression did not show prognostic differences when samples 
from all the subtypes were included or when all samples were segre-
gated by KRAS status (Supplementary Fig. 7h–k). Our observation 
of elevated FLNA expression in CR-TA tumors then led us to examine 
the effects on proliferation of pharmacologically inhibiting cMET 
using the selective small-molecule inhibitor PFA-665752 in a panel 
of transit-amplifying cell lines. We found that CR-TA cell lines were 
more sensitive to cMET inhibition than CS-TA cell lines (Fig. 3j). 
Moreover, we found that three transit-amplifying–subtype samples 
from Supplementary Figure 2g could be assigned to CR-TA or CS-TA 
sub-subtypes (Supplementary Fig. 7l,m) using a qRT-PCR assay for 
FLNA (one of the seven genes of CRCassigner-7 signature) expres-
sion. We did not find a significant association between the transit- 
amplifying subtype and KRAS mutation status (P = 0.1; chi-square test; 
Supplementary Results and Discussion, Fig. 3h and Supplementary 
Fig. 7n–q). Collectively, these results suggest that screening first for 
the transit-amplifying subtype with CFTR expression followed by 
FLNA expression using qRT-PCR assays (Supplementary Fig. 7l,m) 
to subdivide the transit-amplifying subtype into two sub-subtypes 
could provide an effective means to predict sensitivity to either 
cetuximab (low FLNA) or to a cMET inhibitor (high FLNA) in patients 
with metastatic, transit-amplifying cancer.
We next examined the possibility that the subtypes might show dif-
ferential responses to a chemotherapy regimen deployed in first-line 
treatment of patients with metastatic CRC (FOLFIRI, a combina-
tion of irinotecan, 5-fluorouracil, and leukovorin)1. This evaluation 
was performed by NMF consensus clustering using a gene expres-
sion profile data set (Del Rio data set) of primary CRC samples from 
patients with metastatic disease with matched FOLFIRI response 
data34. We found that 71% of stem-like–subtype tumors (n = 7) in this 
data set were associated with clinical benefit to FOLFIRI treatment, 
whereas only 29% (n = 14) of tumors from the other subtypes were 
associated with the treatment benefit (Fig. 4a and Supplementary 
Fig. 8a–c). We further tested this association by showing that stem-
like samples (100%, n = 18) were significantly (FDR < 0.2) associated 
with the FOLFIRI response signature35 in the patients with meta-
static disease (Fig. 4b) in the Khambata-Ford data set32, using the 
NTP algorithm23.
Similarly, the FOLFIRI response signature35 was significantly 
(FDR < 0.2) associated with 100% (n = 74) of the stem-like– and 75% 
(n = 53) of the inflammatory-subtype samples, as compared to only 
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Figure 4 Specific response to chemotherapy in CRC subtypes. (a) Heatmap showing individual responses  
of patients with primary CRC (Del Rio data set34, n = 21) to FOLFIRI treatment and their association with  
subtypes. The subtypes in the Del Rio data set were identified after merging the data set with the core CRC  
data sets (Supplementary Fig. 8c). Complete and partial responses and stable disease were considered  
as beneficial response, whereas progressive disease was deemed as no response. (b,c) Heatmaps showing  
association of individual patient CRC responses in the Khambata-Ford data set (metastases) (b) and in  
the core data sets (includes samples from all of the Dukes’ stages) (c) to FOLFIRI by applying published  
FOLFIRI response signatures35 using the NTP algorithm. In these analyses, statistics include only those  
samples that were predicted with FDR < 0.2. (d) CRC subtype–specific cell line response to FOLFIRI  
components. Namely, the combination of 5-FU (239 µM) and irinotecan (22.5 µM), plotted as percentage cellular proliferation and normalized to 
vehicle-treated cells. Error bars represent the s.d. of technical replicates from a representative experiment. *P < 0.05. TA, transit amplifying.
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14% (n = 56) of the transit-amplifying–, 39% (n = 33) of the goblet-
like– and 38% (n = 40) of the enterocyte–subtype tumors in the core 
CRC data sets (comprised of all Dukes’ stage samples; Fig. 4c and 
Supplementary Fig. 8d–f) as assessed using the NTP algorithm. We 
experimentally assessed the association of the stem-like CRC subtype 
with sensitivity to FOLFIRI in a panel of eight CRC cell lines repre-
senting different transcriptional subtypes. We treated these cell lines 
with 5-fluorouracil (5-FU) plus irinotecan (the two chemotherapy 
components of FOLFIRI). Three of the four most sensitive cell lines 
were of the stem-like subtype (Fig. 4d). These results are consistent 
with the data presented in Figure 1e and Supplementary Figure 5a–d, 
demonstrating that patients with stem-like tumors have improved 
DFS when treated with chemotherapy or chemoradiotherapy in the 
adjuvant setting. This finding is also consistent with data from poor-
prognosis subtypes identified in other cancer types, such as basal 
and claudin-low breast cancer36 and quasi-mesenchymal pancreatic 
ductal adenocarcinoma5, which are comparatively more responsive 
to chemotherapy than other subtypes.
In summary, we document the existence of six subtypes of CRC 
based on the combined analysis of gene expression profiles and dif-
ferential response to cetuximab. These subtypes are phenotypically 
distinct in their DFS (Fig. 5a) and vary in degree of response to cetux-
imab and standard-of-care chemotherapy. We also have shown that 
these CRC subtypes are associated with distinctive anatomical regions 
of the colon crypts (phenotype) and with location-dependent dif-
ferentiation states and Wnt signaling activity (Fig. 5b). We identified 
candidate biomarkers that might be developed into clinical qRT-PCR 
or immunohistochemical assays to classify CRC tumors into one of 
six subtypes (Fig. 5c) as a guide to assignment of subtype-specific 
therapeutic agents (Fig. 5d). With regard to first-line chemotherapy, 
we infer that particular subtypes might show beneficial responses to 
FOLFIRI in either adjuvant or metastatic settings (Fig. 5d), whereas in 
unselected CRC this treatment did not improve survival in the adju-
vant setting37. Our analyses suggest that stem-like–subtype tumors, 
both in the adjuvant and metastatic settings, as well as inflammatory- 
subtype tumors in the adjuvant setting, may best be treated with 
FOLFIRI. Additionally, the transit-amplifying sub-subtypes and the 
goblet-like subtype will probably not respond to FOLFIRI in the adju-
vant setting. Watchful surveillance might spare patients with these 
forms of disease from the harmful side effects of debilitating and inef-
fective FOLFIRI treatment. Moreover, and in contrast to the adjuvant 
setting, the CS-TA or CR-TA subtype might be effectively treated 
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Figure 5 Summary, including clinically deployable markers and potential subtype-guided therapies for CRC. (a) Salient characteristics of the six  
CRC subtypes. Int, intermediate DFS; Either, either crypt top or base; NA, no clear association. (b) CRC subtype phenotypes correlated with  
colon-crypt location and Wnt signaling. (c) Summary of subtype-specific candidate biomarkers (CRCassigner-7) that were tested using qRT-PCR 
and immunohistochemistry (IHC), and (d) subtype guided therapeutic strategies suggested by the association studies. ZEB1 was not useful for 
qRT-PCR because ZEB1 is expressed both by fibroblast and tumor cells. The expression of ZEB1 specifically in tumor cells was evaluated using 
immunohistochemistry as in Figure 1c. TBD, to be determined.
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with cetuximab or a cMET inhibitor, respectively, in the metastatic 
setting (Fig. 5d). These associations warrant further retrospective and 
prospective validation. Lastly, we demonstrated that subtype-specific 
CRC cell lines and xenograft tumors can serve as surrogates for 
assessing subtype-specific treatment responses. Recognition of these 
subtypes may prove applicable to the assessment of new investiga-
tional drugs in preclinical trials. The outcomes could in turn guide 
‘personalized’ therapeutic trial designs that target subtype-selective 
sensitivities in those patients with CRC who are most likely to see 
clinical benefit, much as is becoming standard of care in non– 
small-cell lung cancer38.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METhODS
Combining different microarray data sets. Microarray data sets from dif-
ferent published studies were screened separately for variable genes using s.d. 
cut off greater than 0.8. The screened data sets were column (sample) normal-
ized to N(0,1) and row (gene) normalized and then merged using Java-based 
distance-weighted discrimination14. Finally, the rows were median centered 
before further downstream analysis, as described5. Additional methodologi-
cal details can be found in the Supplementary Methods and Supplementary 
Results and Discussion.
NMF, SAM and PAM analysis. The stable subtypes were identified using con-
sensus clustering-based NMF11 followed by SAM16 (using classes defined by 
NMF analysis) and PAM17 (using significant genes defined by SAM) analysis to 
identify gene signature specific to each of the subtypes with modified methods 
described for glioblastoma classification2. Additional methodological details 
can be found in the Supplementary Methods and Supplementary Results 
and Discussion.
Drug response in cell lines using proliferation assay. Cells were 
added (5 × 103) into 96-well plates on day 0 and treated with cetuximab 
(Merck Serono, Geneva, Switzerland), cMET inhibitor (PHA-665752, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), a combination of 5-FU 
(Sigma-Aldrich, Buchs SG, Switzerland) and irinotecan (Pfizer AG, Zurich, 
Switzerland) or vehicle control (medium alone or DMSO) in the presence of 
fetal bovine serum on day 1. Proliferation was monitored using CellTiter-Glo 
assay kit according to the manufacturer’s instructions (Promega, Dubendorf, 
Switzerland) on day 3 (72 h).
TOP flash assay. The TOP/FOP-flash assay was performed as instructed by 
the manufacturer (Upstate, USA). Briefly, colon cancer cell lines were plated 
into 24-well dishes in biological triplicate at 10,000 cells/well in full growth 
medium (RPMI + 10% FBS). The next day, the medium was changed to that 
containing 3 µL of polyethylenimine (stock, 1 mg mL−1), TOP or FOP-flash 
DNA (0.25 µg/well) and a plasmid encoding constitutive expression of Renilla 
luciferase (to normalize for transfection efficiency). Two days later, the cells 
were assayed. Samples were prepared in biological triplicate (n = 3) and the 
experiment was repeated twice.
Additional methods. Detailed methodology is described in the Supplementary 
Methods.
